Mr Tom Palenius Finland

Abacus Diagnostica Oy is a Finnish molecular diagnostics company specialized in rapid DNA testing utilizing its proprietary GenomEra™ technology.

Abacus Diagnostica provides reliable, pathogen specific, easy to use solutions to enable routine use of DNA based testing when infections with critical pathogens are suspected and high sensitivity is needed.

Abacus Diagnostica’s sales are organized through distributors, currently with partners in Finland and 8 other European countries. Totally 33 systems are already placed in Europe, of which half are in routine use. 

PRODUCTS AVAILABLE (CE-IVD):

  • GenomEra CDX™ Analyzer System 
  • GenomEra MRSA/SA Blood Culture Test Kit
  • GenomEra MRSA/SA Nasal Swab Test Kit
  • GenomEra MRSA/SA Multi Swab Test Kit
  • GenomEra MRSA/SA Diagnose Test Kit
  • GenomEra Clostridium difficile Test Kit (available for evaluation Sep 2012)

To accelerate sales and growth, Abacus is now seeking for a capital investment to be targeted on three main topics:

  1. Boosting sales by accelerating Europe and entering the US market
  2. Widening the the test kit portfolio,  and
  3. Increasing production capacity both for test chips and analyzers. 
Mr Tom Palenius
Abacus Diagnostica
LinkedIn logo CEO 

Dr Christos Panotopoulos Sweden

Serendipity's core business is to create new innovative companies based on leading academic research.

Serendipity does this together with leading researchers, motivated entrepreneurs and by working closely with potential customers to ensure that the products and services developed meet the actual needs and requirements of the market. Our product development projects usually involve paying customers. This makes the value creation process more efficient while the product demand becomes more predictable.  

Serendipity began operations in 2004 and has since established and operated more than ten companies; most of them research and development-intensive companies.

Serendipity Innovations
Medical Advisor 

Mr Carl Pereswetoff-Morath Sweden

Invest Sweden
Investment Advisor 

Jesper Pettersson

Create

Ms Helena Peyron Denmark

BioMed Community is a life science cluster in north Denmark.

The community is a collaboration between 55 MedTech companies, Aalborg University, Aalborg Hospital, the City of Aalborg and the Aalborg Co-operation. 

The main objective for BioMed Community is to foster innovation and generate growth by supporting our local entrepreneurs and enterprises engaged in health technology.

BioMed Community

Professor Claes Post Sweden

Business Type
ALMI INVEST AB
Investment Manager